Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19073950 | METHODS OF ASSAYING PHOSPHORYLATED TAU PROTEIN IN A SAMPLE | March 2025 | December 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 17916993 | PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | October 2022 | March 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17995261 | ANTIBODIES THAT SPECIFICALLY BIND PEPTIDES ASSOCIATED WITH THE PRIMARY IMMUNODEFICIENCIES: WISKOTT-ALDRICH SYNDROME AND X-LINKED AGAMMAGLOBULINEMIA | September 2022 | September 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17742076 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | May 2022 | October 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17734211 | SYSTEMS FOR PROVIDING A PROBABILITY OF PROSTATE CANCER RISK AND/OR PROSTATE GLAND VOLUME, AND RELATED METHODS | May 2022 | February 2026 | Allow | 46 | 3 | 1 | Yes | No |
| 17772238 | IMPROVED PROCESSES FOR RATIONALLY-DESIGNING AND PRODUCING BIOMOLECULES | April 2022 | February 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17729494 | MULTIPLEX MICROELECTRODE ARRAY FOR DETECTION OF PROTEASES AS BIOMARKERS | April 2022 | January 2026 | Allow | 45 | 3 | 1 | Yes | No |
| 17685705 | ANTI-DRUG ANTIBODY ASSAY | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17638307 | KAWASAKI DISEASE DETERMINATION KIT AND KAWASAKI DISEASE DETERMINATION METHOD | February 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17674968 | METHODS OF PRODUCING BODILY FLUID SAMPLES CONTAINING AN ANALYTICALLY QUANTIFIED AMOUNT OF PHOSPHORYLATED TAU PROTEIN | February 2022 | January 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17591521 | QUANTITATIVE BIOMARKERS FOR ASSESSING MILD TRAUMATIC BRAIN INJURY AND METHODS OF USE THEREOF | February 2022 | October 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17578728 | DETECTION OF MISFOLDED TAU PROTEIN | January 2022 | March 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17575186 | S100A6 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17457279 | Method and reagents for diagnosing Membranous Nephropathy | December 2021 | July 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17608069 | METHOD FOR THE DETECTION OF CANCER | November 2021 | February 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17594729 | SELECTION OF FIBROBLAST DONORS FOR OPTIMIZATION OF ALLOGENEIC FIBROBLAST-MEDIATED REGENERATION | October 2021 | November 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17599531 | POROUS HOLLOW FIBER MEMBRANE AND METHODS OF USING IT TO SELECT IMMUNE CHECKPOINT INHIBITOR | September 2021 | August 2025 | Allow | 46 | 1 | 1 | No | No |
| 17471622 | METHOD OF FABRICATING SUBSTRATE FOR ANALYSIS, SUBSTRATE FOR ANALYSIS, AND ANALYSIS UNIT | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17437094 | METHODS FOR ASSESSING CARDIOVASCULAR DISEASE OR INFLAMMATORY DISEASE RISK USING NON-EXCHANGEABLE LIPID PROBE | September 2021 | February 2026 | Allow | 53 | 3 | 0 | Yes | No |
| 17437118 | A Method for Separating Biomolecules | September 2021 | December 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17436794 | IMMUNOASSAY METHOD FOR B-D-GLUCAN IN BIOLOGICAL SAMPLE, AND AN ASSAY KIT FOR B-D-GLUCAN | September 2021 | August 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17435109 | METHOD AND KIT FOR MEASURING APP669-711 | August 2021 | November 2025 | Abandon | 51 | 2 | 1 | Yes | No |
| 17291129 | METHOD FOR DETECTING VIRAL LIVER CANCER | May 2021 | December 2025 | Abandon | 56 | 2 | 1 | Yes | No |
| 17141586 | COLLAGEN IV BINDING ASSAY FOR THE DETECTION OF COLLAGEN VII | January 2021 | November 2025 | Abandon | 58 | 1 | 1 | No | No |
| 17256040 | Biosensor for Diagnosis of Thyroid Dysfunction | December 2020 | September 2025 | Abandon | 56 | 0 | 2 | No | No |
| 17009225 | Automated method for direct sampling of immune cells from whole blood or other biological samples in microwell plates | September 2020 | July 2025 | Allow | 59 | 5 | 1 | Yes | No |
| 16959653 | CIRCULATING BIOMARKER SIGNATURES FOR LYME DISEASE DIAGNOSIS AND TREATMENT | July 2020 | April 2025 | Abandon | 58 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner IVICH, FERNANDO NMN works in Art Unit 1678 and has examined 14 patent applications in our dataset. With an allowance rate of 35.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner IVICH, FERNANDO NMN's allowance rate of 35.7% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by IVICH, FERNANDO NMN receive 1.79 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by IVICH, FERNANDO NMN is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +54.2% benefit to allowance rate for applications examined by IVICH, FERNANDO NMN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.